Actively Recruiting
Atezolizumab and BEvacizumab With STereotactic Body Radiotherapy for Advanced Hepatocellular Carcinoma
Led by Yonsei University · Updated on 2024-11-01
33
Participants Needed
1
Research Sites
199 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To determine the efficacy and safety of atezolizumab-bevacizumab combination therapy plus stereotactic body radiotherapy(SBRT) in patients with advanced hepatocellular carcinoma, Subjects will start SBRT for one or more primary cancers and/or metastatic lesions and no more than 5 sites within two month before and after the start date of atezolizumab-bevacizumab combination therapy. In this study, it is expected to improve the treatment response rate of atezolizumab-bevacizumab therapy, which is currently first-line chemotherapy but has a low treatment response rate.
CONDITIONS
Official Title
Atezolizumab and BEvacizumab With STereotactic Body Radiotherapy for Advanced Hepatocellular Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 19 to 80 years old
- Liver function Child-Pugh class A
- ECOG performance status 0 or 1
- Clinical or pathological diagnosis of hepatocellular carcinoma
- Advanced hepatocellular carcinoma that cannot be surgically removed
- Able to receive radiotherapy within dose limits for normal organs and lesions of appropriate size
You will not qualify if you...
- Presence of brain metastases
- History of malignancy other than hepatocellular carcinoma within the last 5 years (except low-risk cancers like treated cervical carcinoma in situ, non-melanoma skin cancer, localized prostate cancer, tubular carcinoma in situ, or stage 1 uterine cancer)
- High risk of untreated gastric or esophageal varices or bleeding
- Serious uncontrolled medical conditions
- History of liver transplant surgery
- Autoimmune liver disease
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Yongin Severance Hospital
Yongin-si, South Korea, 365
Actively Recruiting
Research Team
H
Hwakyung BYUN, Phd
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here